Quick Asked: Genevant Sciences Contact Us?
Last update: 01 May, 2024 
316 Views
What is genevant sciences? In April 2018, Arbutus together with Roivant launched Genevant Sciences, a new jointly-owned company focused on the discovery, development, and commercialization of novel RNA-based therapeutics enabled by Arbutus’ LNP and ligand conjugate delivery technologies (collectively, the Delivery Technologies).How many employees does genevant have? Genevant has 34 employees. Who are Genevant competitors? Competitors of Genevant include Metacrine, Vitrolife and Novadip Biosciences. Where is Genevant headquarters?How many rna programs does genevant have in the clinic? By 2020, Genevant aims to have 5 to 10 RNA programs in the clinic targeting a range of genetic disorders with limited or no treatment options. In addition to its equity interest in Genevant, Arbutus is entitled to royalties on future sales of products enabled by Arbutus’ LNP and ligand conjugate delivery technologies.What is genegenevants lnp platform? Genevant offers a lipid nanoparticle (LNP) platform that enables clinical development of RNA-based therapeutics. Its proprietary ligand conjugate delivery platform has been designed for RNAi therapeutics targeting the liver.
Listing Results Genevant Sciences Contact Us? Question Answers
Genevant Pipeline Arbutus Biopharma
Genevant. In April 2018, Arbutus together with Roivant launched Genevant Sciences, a new jointly-owned company focused on the discovery, development, and commercialization of novel RNA-based therapeutics enabled by Arbutus’ LNP and ligand conjugate delivery technologies (collectively, the Delivery Technologies). Arbutus has licensed exclusive
Our team Genevant Sciences Corporation
Ed Yaworski has served as Chief Technology Officer of Genevant Sciences Corporation since November 2021. Previously, he was VP, Pharmaceutical Development. Prior to joining Genevant at its inception in April 2018, Ed directed and led CMC activities at Arbutus Biopharma. He brings nearly 30 years of experience in the pharmaceutical industry
Genevant Sciences MassBio
Through our industry-leading lipid nanoparticle (LNP) and ligand conjugate delivery platforms, we are able to select and pursue the optimal approach for any given disease. We intend to discover and develop products in-house and form partnerships to build a diverse pipeline of therapeutics across leading RNA modalities, including RNAi, mRNA, and gene editing.